Identification of human reductases that activate the dinitrobenzamide mustard prodrug PR-104A: A role for NADPH:cytochrome P450 oxidoreductase under hypoxia

Biochemical Pharmacology

Volumn 74, Issue 6, 2007, Pages 810-820

  Guise, Chris P ^a   Wang, Anderson T ^a   Theil, Anke ^a   Bridewell, David J ^a   Wilson, William R ^a   Patterson, Adam V ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Cancer; Hypoxia; Metabolism; Oxidoreductase; Prodrug; Reductive

Indexed keywords

3,5 DINITROBENZAMIDE 2 NITROGEN MUSTARD; ANTISENSE OLIGODEOXYNUCLEOTIDE; DIPHENYLIODONIUM SALT; DRUG METABOLITE; MUSTARD GAS DERIVATIVE; PR 104A; PRODRUG; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL PROTECTION; CELL STRAIN HT29; CONTROLLED STUDY; CORRELATION ANALYSIS; CULTURE MEDIUM; DRUG ACTIVATION; DRUG CYTOTOXICITY; DRUG METABOLISM; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HYPOXIA; IC 50; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ANTINEOPLASTIC AGENTS; CELL DEATH; CELL HYPOXIA; CELL LINE, TUMOR; HUMANS; NAD(P)H DEHYDROGENASE (QUINONE); NADPH-FERRIHEMOPROTEIN REDUCTASE; NITROGEN MUSTARD COMPOUNDS; OXIDOREDUCTASES; PRODRUGS;

EID: 34547653834     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2007.06.014     Document Type: Article

References (59)

1. Vaupel P. Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol 14 (2004) 198-206
2. Wouters B.G., Weppler S.A., Koritzinsky M., Landuyt W., Nuyts S., Theys J., et al. Hypoxia as a target for combined modality treatments. Eur J Cancer 38 (2002) 240-257
3. Hockel M., and Vaupel P. Biological consequences of tumor hypoxia. Semin Oncol 28 (2001) 36-41
4. Subarsky P., and Hill R.P. The hypoxic tumour microenvironment and metastatic progression. Clin Exp Metastasis 20 (2003) 237-250
5. Brown J.M., and Wilson W.R. Exploiting tumor hypoxia in cancer treatment. Nature Rev Cancer 4 (2004) 437-447
6. Boyle R.G., and Travers S. Hypoxia: targeting the tumour. Curr Med Chem - Anti-Cancer Agents 6 (2006) 281-286
7. Patterson A.V., Ferry D.M., Edmunds S.J., Gu Y., Singleton R.S., Patel K., et al. Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA crosslinking agent PR-104. Clin Cancer Res 13 (2007) 3922-3932
8. Siim B.G., Denny W.A., and Wilson W.R. Nitro reduction as an electronic switch for bioreductive drug activation. Oncol Res 9 (1997) 357-369
9. Helsby N.A., Wheeler S.J., Pruijn F.B., Palmer B.D., Yang S., Denny W.A., et al. Effect of nitroreduction on the alkylating reactivity and cytotoxicity of the 2,4-dinitrobenzamide-5-aziridine CB 1954 and the corresponding nitrogen mustard SN 23862: distinct mechanisms of bioreductive activation. Chem Res Toxicol 16 (2003) 469-478
10. Hicks KO, Myint H, Siim BG, Pruijn FB, Patterson AV, Patel K et al. Oxygen dependence and extravascular transport of hypoxia-activated prodrugs: comparison of the dinitrobenzamide mustard PR-104A and tirapazamine. Int J Radiat Oncol Biol Phys, in press.
11. Patel K, Gu Y, Lewiston D, Hicks KO, Wilson WR. Analysis of the hypoxia-activated dinitrobenzamide mustard phosphate prodrug PR-104 and its alcohol metabolite PR-104A in plasma and tissues by liquid chromatography-mass spectrometry. J Chromatogr B, doi:10.1016/j.jchromb.2007.06.035.
12. Wilson W.R., Hicks K.O., Pullen S.M., Ferry D.M., Helsby N.A., and Patterson A.V. Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards. Radiat Res 167 (2007) 625-636
13. Stratford I.J., and Workman P. Bioreductive drugs into the next millennium. Anticancer Drug Des 13 (1998) 519-528
14. Workman P. Enzyme-directed bioreductive drug development revisited: a commentary on recent progress and future prospects with emphasis on quinone anticancer agents and quinone metabolizing enzymes, particularly DT-diaphorase. Oncol Res 6 (1994) 461-475
15. Wardman P. Electron transfer and oxidative stress as key factors in the design of drugs selectively active in hypoxia. Curr Med Chem 8 (2001) 739-761
16. Ross D., Beall H., Traver R.D., Siegel D., Phillips R.M., and Gibson N.W. Bioactivation of quinones by DT-diaphorase, molecular, biochemical, and chemical studies. Oncol Res 6 (1994) 493-500
17. Beall H.D., Murphy A.M., Siegel D., Hargreaves R.H.J., Butler J., and Ross D. Nicotinamide adenine dinucleotide (phosphate):quinone oxidoreductase (DT-diaphorase) as a target for bioreductive antitumor quinones: quinone cytotoxicity and selectivity in human lung and breast cancer cell lines. Mol Pharmacol 48 (1995) 499-504
18. Winski S.L., Swann E., Hargreaves R.H., Dehn D.L., Butler J., Moody C.J., et al. Relationship between NAD(P)H:quinone oxidoreductase 1 (NQO1) levels in a series of stably transfected cell lines and susceptibility to antitumor quinones. Biochem Pharmacol 61 (2001) 1509-1516
19. Ross D., and Siegel D. NAD(P)H:quinone oxidoreductase 1 (NQO1, DT-diaphorase), functions and pharmacogenetics. Methods Enzymol 382 (2004) 115-144
20. Skelly J.V., Knox R.J., and Jenkins T.C. Aerobic nitroreduction by flavoproteins: enzyme structure, mechanisms and role in cancer chemotherapy. Mini Rev Med Chem 1 (2001) 293-306
21. Joseph P., Xie T., Xu Y., and Jaiswal A.K. NAD(P)H: quinone oxidorereductase (DT-diaphorase): expression, regulation, and role in cancer. Oncol Res 6 (1994) 525-532
22. Chen S., Knox R., Wu K., Deng P.S., Zhou D., Bianchet M.A., et al. Molecular basis of the catalytic differences among DT-diaphorase of human, rat and mouse. J Biol Chem 272 (1997) 1437-1439
23. Knox R.J., Friedlos F., Jarman M., and Robert J.J. A new cytotoxic, DNA interstrand crosslinking agent, 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide, is formed from 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by nitroreductase enzyme in Walker carcinoma cells. Biochem Pharmacol 37 (1988) 4661-4669
24. Boland M.P., Knox R.J., and Roberts J.J. The differences in kinetics of rat and human DT diaphorase result in a differential sensitivity of derived cell lines to CB 1954 (5-(aziridin-1-yl)-2,4-dinitrobenzamide). Biochem Pharmacol 41 (1991) 867-875
25. Cénas N., Anusevicius Z., Bironaité D., Bachmanova G.I., Archakov A.I., and Öllinger K. The electron transfer reactions of NADPH:cytochrome P450 reductase with nonphysiological oxidants. Arch Biochem Biophys 315 (1994) 400-406
26. Bailey S.M., Lewis A.D., Patterson L.H., Fisher G.R., Knox R.J., and Workman P. Involvement of NADPH: cytochrome P450 reductase in the activation of indoloquinone EO9 to free radical and DNA damaging species. Biochem Pharmacol 62 (2001) 461-468
27. Saunders M.P., Jaffar M., Patterson A.V., Nolan J., Naylor M.A., Phillips R.M., et al. The relative importance of NADPH: cytochrome c (P450) reductase for determining the sensitivity of human tumour cells to the indolequinone EO9 and related analogues lacking functionality at the C-2 and C-3 positions. Biochem Pharmacol 59 (2000) 993-996
28. Patterson A.V., Saunders M.P., Chinje E.C., Patterson L.H., and Stratford I.J. Enzymology of tirapazamine metabolism: a review. Anticancer Drug Des 13 (1998) 541-573
29. Butler J., and Hoey B.M. The one-electron reduction potential of several substrates can be related to their reduction rates by cytochrome P-450 reductase. Biochim Biophys Acta 1161 (1993) 73-78
30. Denny WA, Atwell GJ, Yang S, Wilson WR, Patterson AV, Helsby NA. Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents. 2005 patent; WO 2005/042471 A1.
31. Patterson A.V., Saunders M.P., Chinje E.C., Talbot D.C., Harris A.L., and Stratford I.J. Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069. Br J Cancer 76 (1997) 1338-1347
32. Patterson A.V., Robertson N., Houlbrook S., Stephens M.A., Adams G.E., Harris A.L., et al. The role of DT-diaphorase in determining the sensitivity of human tumor cells to tirapazamine (SR 4233). Int J Radiat Oncol Biol Phys 29 (1994) 369-372
33. Ahn G.O., Botting K.J., Patterson A.V., Ware D.C., Tercel M., and Wilson W.R. Radiolytic and cellular reduction of a novel hypoxia-activated cobalt(III) prodrug of a chloromethylbenzindoline DNA minor groove alkylator. Biochem Pharmacol 71 (2006) 1683-1694
34. Sharp S.Y., Kelland L.R., Valenti M.R., Brunton L.A., Hobbs S., and Workman P. Establishment of an isogenic human colon tumor model for NQO1 gene expression: application to investigate the role of DT-diaphorase in bioreductive drug activation in vitro and in vivo. Mol Pharmacol 58 (2000) 1146-1155
35. Osada M., Imaoka S., Sugimoto T., Hiroi T., and Funae Y. NADPH-cytochrome P-450 reductase in the plasma membrane modulates the activation of hypoxia-inducible factor 1. J Biol Chem 277 (2002) 23367-23373
36. Hay M.P., Gamage S.A., Kovacs M.S., Pruijn F.B., Anderson R.F., Patterson A.V., et al. Structure-activity relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamine. J Med Chem 46 (2003) 169-182
37. Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82 (1990) 1107-1112
38. Smith P.K., Krohn R.I., Hermanson G.T., Mallia A.K., Gartner F.H., Provenzano M.D., et al. Measurement of protein using bicinchoninic acid. Anal Biochem 150 (1985) 76-85 [erratum appears in Anal Biochem 1987 May 15;163(1):279]
39. Ernster L., Lind C., and Rase B. A study of the DT-diaphorase activity of warfarin-resistant rats. Eur J Biochem 25 (1972) 198-206
40. Wu K., Eng E., Knox R., and Chen S. Demonstration of the activation of prodrug CB 1954 using human DT-diaphorase mutant Q104Y-transfected MDA-MB-231 cells and mouse xenograft model. Arch Biochem Biophys 385 (2001) 203-208
41. Belcourt M.F., Hodnick W.F., Rockwell S., and Sartorelli A.C. Bioactivation of mitomycin antibiotics by aerobic and hypoxic Chinese hamster ovary cells overexpressing DT-diaphorase. Biochem Pharmacol 51 (1996) 1669-1678
42. Tew D.G. Inhibition of cytochrome P450 reductase by the diphenyliodonium cation. Kinetic analysis and covalent modifications. Biochemistry (Mosc) 32 (1993) 10209-10215
43. Rooseboom M., Commandeur J.N., and Vermeulen N.P. Enzyme-catalyzed activation of anticancer prodrugs. Pharmacol Rev 56 (2004) 53-102
44. Knox R.J., and Chen S. Quinone reductase-mediated nitro-reduction: clinical applications. Methods Enzymol 382 (2004) 194-221
45. Knox R.J., Boland M.P., Friedlos F., Coles B., Southan C., and Roberts J.J. The nitroreductase enzyme in Walker cells that activates 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) to 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide is a form of NAD(P)H dehydrogenase (quinone) (EC 1.6.99.2). Biochem Pharmacol 37 (1988) 4671-4677
46. Beall H.D., Mulcahy R.T., Siegal D., Traver R.D., Gibson N.W., and Ross D. Metabolism of bioreductive antitumor compounds by purified rat and human DT-diaphorases. Cancer Res 54 (1994) 3196-3201
47. Palmer B.D., Wilson W.R., Atwell G.J., Schultz D., Xu X.Z., and Denny W.A. Hypoxia-selective antitumor agents. 9. Structure-activity relationships for hypoxia-selective cytotoxicity among analogues of 5-[N,N-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide. J Med Chem 37 (1994) 2175-2184
48. McNally V.A., Patterson A.V., Williams K.J., Cowen R.L., Stratford I.J., and Jaffar M. Antiangiogenic, bioreductive and gene therapy approaches to the treatment of hypoxic tumours. Curr Pharm Des 8 (2002) 1319-1333
49. Walton M.I., Wolf C.R., and Workman P. Molecular enzymology of the reductive bioactivation of hypoxic cell cytotoxins. Int J Radiat Oncol Biol Phys 16 (1989) 983-986
50. Backes W.L., and Kelley R.W. Organization of multiple cytochrome P450s with NADPH-cytochrome P450 reductase in membranes. Pharmac Ther 98 (2003) 221-233
51. O'Donnell V.B., Smith G.C., and Jones O.T. Involvement of phenyl radicals in iodonium inhibition of flavoenzymes. Mol Pharmacol 46 (1994) 778-785
52. Coves J., Lebrun C., Gervasi G., Dalbon P., and Fontecave M. Overexpression of the FAD-binding domain of the sulphite reductase flavoprotein component from Escherichia coli and its inhibition by iodonium diphenyl chloride. Biochem J 342 (1999) 465-472
53. Riganti C., Gazzano E., Polimeni M., Costamagna C., Bosia A., and Ghigo D. Diphenyleneiodonium inhibits the cell redox metabolism and induces oxidative stress. J Biol Chem 279 (2004) 47726-47731
54. Fitzsimmons S.A., Workman P., Grever M., Paull K., Camalier R., and Lewis A.D. Reductase enzyme expression across the National Cancer Institute Tumor cell line panel: correlation with sensitivity to mitomycin C and EO9. J Natl Cancer Inst 88 (1996) 259-269
55. Yu L.J., Matias J., Scudiero D.A., Hite K.M., Monks A., Sausville E.A., et al. P450 enzyme expression patterns in the NCI human tumor cell line panel. Drug Metab Dispos 29 (2001) 304-312
56. Philip P.A., Kaklamanis L., Ryley N., Stratford I., Wolf R., Harris A., et al. Expression of xenobiotic-metabolizing enzymes by primary and secondary hepatic tumors in man. Int J Radiat Oncol Biol Phys 29 (1994) 277-283
57. Lopez dC, Marin A., Idoate M.A., Tunon M.T., and Bello J. Carbonyl reductase and NADPH cytochrome P450 reductase activities in human tumoral versus normal tissues. Eur J Cancer 35 (1999) 320-324
58. Plewka D., Plewka A., Nowaczyk G., Kaminski M., Rutkowski T., Ludyga T., et al. Neoplastic lesions of the human liver in relation to the activity of the cytochrome P-450 dependent monooxygenase system. Med Sci Monitor 6 (2000) 244-248
59. Basu S., Brown J.E., Flannigan G.M., Gill J.H., Loadman P.M., Martin S.W., et al. Immunohistochemical analysis of NAD(P)H:quinone oxidoreductase and NADPH cytochrome P450 reductase in human superficial bladder tumours: relationship between tumour enzymology and clinical outcome following intravesical mitomycin C therapy. Int J Cancer 109 (2004) 703-709